You are here

Bristol-Myers investors feel the harsh downside of cancer bet

New York

FOR almost four years, Bristol-Myers Squibb Co investors have profited handsomely thanks to the company's sharp focus on cancer. On Friday, they felt the other side of that concentrated bet.

The drop in the shares on Friday - the worst in more than 16 years - had as much